Methods of treating acute myeloid leukemia

ABSTRACT

A method of treating acute myeloid leukemia (AML), including the steps of (i) measuring a density of blast cells in the peripheral blood and the bone marrow of a subject with AML; (ii) administering to the subject a CXCR4 antagonist; and (iii) administering to the subject a therapeutically effective amount of the CXCR4 antagonist and a therapeutically effective amount of a chemotherapeutic agent, if the blast cell density in the peripheral blood is less than 10% of the total peripheral white blood cells, or at least five-fold lower than the blast cell density in the bone marrow, or at least two-fold higher one day or more following step (ii).

RELATED APPLICATIONS

This application is a National Phase of PCT Patent Application No. PCT/IL2017/050232 having International filing date of Feb. 23, 2017, which claims the benefit of priority under 35 USC § 119(e) of U.S. Provisional Patent Application No. 62/298,563 filed on Feb. 23, 2016. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.

SEQUENCE LISTING STATEMENT

The ASCII file, entitled 74824SequenceListing.txt, created on Aug. 22, 2018, comprising 39,765 bytes, submitted concurrently with the filing of this application is incorporated herein by reference. The sequence listing submitted herewith is identical to the sequence listing forming part of the international application.

FIELD AND BACKGROUND OF THE INVENTION

The present invention, in some embodiments thereof, relates to methods of treating acute myeloid leukemia (AML) and, more particularly but not exclusively, to selectively treating AML patients identified for being potentially responsive to a CXCR4 antagonist.

Acute myeloid leukemia is a heterogeneous group of diseases characterized by the uncontrolled proliferation of hematopoietic stem cells and progenitors (blasts) with a reduced capacity to differentiate into mature cells (Estey et al., Lancet 368:1894-1907, 2006). Despite sensitivity to chemotherapeutic, long-term disease-free survival for AML patients remains low and the majority eventually relapse from minimal residual disease (MRD; Matsunaga et al., Nat Med. 9:1158-65, 2003). Bone marrow (BM) is the major site for MRD where adhesion of AML cells to bone marrow components may provide protection from the drugs (Estey et al., Lancet 368:1894-1907, 2006). The chemokine receptor CXCR4 and its ligand stromal derived factor-1 (SDF-1/CXCL12) are important players involved in the cross-talk between leukemia cells and the BM microenvironment (J. A. Burger and A. Peled, Leukemia 23:43-52, 2009).

The bicyclam drug termed AMD3100, originally discovered as an anti-HIV compound, specifically interacts with CXCR4 in an antagonistic manner. Blocking CXCR4 receptor with AMD3100 results in the mobilization of hematopoietic progenitor cells. WO 2007/022523 discloses the use of CXCR4 agonists such as AMD3100 for enhancing the effectiveness of chemotherapeutic methods in subjects afflicted with myeloid or hematopoietic malignancies.

T-140 is a 14-residue synthetic peptide developed as a specific CXCR4 antagonist that suppress HIV-1 (X4-HIV-1) entry to T cells through specific binding to CXCR4 (Tamamura et al., Biochem. Biophys. Res. Commun. 253(3): 877-882, 1998). Subsequently, peptide analogs of T-140 were developed as specific CXCR4-antagonisic peptides with inhibitory activity at nanomolar levels [Tamamura et al. (Org. Biomol. Chem. 1: 3663-3669, 2003), WO 2002/020561, WO 2004/020462, WO 2004/087068, WO 00/09152, US 2002/0156034, and WO 2004/024178].

WO 2004/087068 discloses antagonists of chemokine receptors, particularly the CXCR4 receptor, and methods of their use, for example, in the treatment, prevention or diagnosis of cancer. The '068 publication discloses that exemplary CXCR4 peptide antagonists include T140 and derivatives of T140, and that the pathology includes cancer such as breast, brain, pancreatic, ovarian, prostate, kidney, and non-small lung cancer.

WO 00/09152 discloses a variety of therapeutic uses for CXCR4 antagonists such as in the treatment of cancer.

WO 2004/024178 discloses the use of a chemokine receptor antagonist as a ligand for the CXCR4 receptor for the apoptosis-inducing treatment and/or the prevention of the metastatic spread of cancer cells in a patient.

U.S. Publication No. 2002/0156034 discloses the use of CXCR4 antagonists for the treatment of hematopoietic cells such as in cancer.

WO 2002/020561 discloses peptide analogs and derivatives of T-140. The 561 publication demonstrates that the claimed peptides are potent CXCR4 inhibitors, manifesting high anti-HIV virus activity and low cytotoxicity.

Recently, a comparative study between the CXCR4 antagonists TN140 and AMD3100 suggested that TN140 is more effective than AMD3100 as a monotherapy in AML. TN140 and to a lesser extend AMD3100 induced regression of human CXCR4-expressing AML cells and targeted the NOD/Shi-scid/IL-2Rγnull (NOG) leukemia-initiating cells (LICs) (Y. Zhang et al., Cell Death and Disease, 2012).

WO 2004/020462 discloses additional novel peptide analogs and derivatives of T-140, including 4F-benzoyl-TN14003. The '462 publication further discloses preventive and therapeutic compositions and methods of using same utilizing T-140 analogs for the treatment of cancer, such as T-Cell leukemia.

Beider et al. (Exp. Hematol. 39:282-92, 2011) reported that 4F-benzoyl-TN14003 exhibits a CXCR4-dependent preferential cytotoxicity toward malignant cells of hematopoietic origin including AML. In vivo, subcutaneous injections of 4F-benzoyl-TN14003 significantly reduced the growth of human AML xenografts.

WO 2014/155376 discloses the use of 4F-benzoyl-TN14003 combined with a chemotherapeutic agent in the treatment of AML.

WO 2015/063768 discloses the use of 4F-benzoyl-TN14003 in the treatment of AML with FLT3 mutation.

Uy et al. (Blood 119: 3917-2924, 2012) describes the use of the CXCR4 antagonist prelixafor (AMD3100) in the treatment of relapsed or refractory AML patients.

SUMMARY OF THE INVENTION

According to an aspect of some embodiments of the present invention there is provided a method of selecting a treatment regimen for a subject having acute myeloid leukemia (AML), the method comprising measuring density of blast cells in peripheral blood and optionally bone marrow of the subject, said subject having been treated with a CXCR4 antagonist, wherein when said blast cell density in said peripheral blood is:

(i) less than 10% of the total peripheral white blood cells;

(ii) at least five-fold lower than said blast cell density in said bone marrow; and/or

(iii) at least two-fold higher one day or more following treatment with said CXCR4 antagonist,

said subject is selected for a combined treatment with said CXCR4 and a chemotherapeutic agent.

According to an aspect of some embodiments of the present invention there is provided a method of maximizing response to treatment of acute myeloid leukemia (AML), the method comprising:

(a) measuring a density of blast cells in peripheral blood and bone marrow of a subject with AML;

(b) administering to said subject a CXCR4 antagonist; and

(c) administering to said subject a therapeutically effective amount of said CXCR4 antagonist and a therapeutically effective amount of a chemotherapeutic agent if said blast cell density in said peripheral blood is:

(i) less than 10% of the total peripheral white blood cells;

(ii) at least five-fold lower than said blast cell density in said bone marrow; and/or

(iii) at least two-fold higher one day or more following step (b);

thereby maximizing response of said subject to AML treatment.

According to an aspect of some embodiments of the present invention there is provided a method of treating AML, the method comprising:

(a) identifying a subject with AML having a density of blast cells being less than 10% of the total white blood cells in the peripheral blood; and

(b) administering to said subject a therapeutically effective amount of a CXCR4-antagonist and a therapeutically effective amount of a chemotherapeutic agent, thereby treating the AML.

According to an aspect of some embodiments of the present invention there is provided a method of treating AML, the method comprising:

(a) identifying a subject with AML having a density of blast cells in the peripheral blood being at least five-fold lower than the density of blast cells in the bone marrow; and

(b) administering to said subject a therapeutically effective amount of a CXCR4-antagonist and a therapeutically effective amount of a chemotherapeutic agent, thereby treating the AML.

According to an aspect of some embodiments of the present invention there is provided a method of treating AML, the method comprising:

(a) identifying a subject with AML exhibiting at least two-fold increase in the density of blast cells in the peripheral blood at least one day following administration of a CXCR4 antagonist to said subject; and

(b) administering to said subject identified in step (a) a therapeutically effective amount of said CXCR4-antagonist and a therapeutically effective amount of a chemotherapeutic agent, thereby treating the AML.

According to an aspect of some embodiments of the present invention there is provided a CXCR4-antagonist and a chemotherapeutic agent in the treatment of AML in a subject in need thereof, wherein the subject is selected having been treated with said CXCR4-antagonist and exhibiting blast cell density in peripheral blood which is:

(i) less than 10% of the total peripheral white blood cells;

(ii) at least five-fold lower than said blast cell density in said bone marrow; and/or

(iii) at least two-fold higher one day or more following treatment with said CXCR4 antagonist, According to some embodiments of the invention, said CXCR4 antagonist is a CXCR4-antagonistic peptide.

According to some embodiments of the invention, said CXCR4-antagonistic peptide is as set forth in SEQ ID NO: 1.

According to some embodiments of the invention, said a density of blast cells in said peripheral blood is less than 5%.

According to some embodiments of the invention, said CXCR4-antagonistic peptide is administered to said subject at a daily dose of 0.1 to 5 mg per kg of body weight.

According to some embodiments of the invention, said CXCR4-antagonistic peptide is administered subcutaneously.

According to some embodiments of the invention, said CXCR4-antagonist is administered to said subject as a single therapy at least one day prior to the administration of said chemotherapeutic agent.

According to some embodiments of the invention, said CXCR4-antagonist is administered to said subject at least one hour prior to the administration of said chemotherapeutic agent.

According to some embodiments of the invention, the chemotherapeutic agent comprises cytarabine (ARA-C).

Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.

In the drawings:

FIG. 1 is a bar graph illustrating the mean initial density of blast cells in the bone marrow (BM) of responsive and non-responsive AML patients prior to their treatment with BL-8040. The bar on the left shows that responsive patients [who achieved complete remission or complete remission with incomplete recovery (CR+CRi+CRp)] had initial BM blast-cell density of 37.8% of total white blood cells. The bar on the right shows that non-responsive patients [who failed to achieve complete remission or complete remission with incomplete recovery (SD+PD)] had initial BM blast-cell density of 40.8% of total white blood cells.

FIG. 2 is a bar graph illustrating the mean initial density of blast cells in the peripheral blood (PB) of responsive and non-responsive AML patients prior to their treatment with BL-8040. The bar on the left shows that responsive patients [who achieved complete remission or complete remission with incomplete recovery (CR+CRi+CRp)] had initial PB blast-cell density of 2.9% of total white blood cells. The bar on the right shows that non-responsive patients [who failed to achieve complete remission or complete remission with incomplete recovery (SD+PD)] had initial PB blast-cell density of 19.3% of total white blood cells.

FIG. 3 is a bar graph illustrating the ratio between the density of PB blast cells of treated patients on day 2 following treatment with BL-8040 and the initial density of PB blast cells of the patients prior to the treatment (grey bars). The PB blast cell densities increased by 2.1 and 4.0 fold in responsive patients (CR and CRi, respectively), but no increase was observed in non-responsive patients (SD and PD).

FIG. 4 is a bar graph illustrating the ratio between the density of PB blast cells of treated patients on day 3 following initial treatment with BL-8040 and the initial density of PB blast cells of the patients prior to the treatment (grey bars). The PB blast cell densities increased by 2.1 and 2.9 fold in responsive patients (CR and CRi, respectively), but no significant increase was observed in non-responsive patients (SD and PD).

FIG. 5 is a bar graph illustrating the ratio between the density of PB blast cells of treated patients on day 3 following initial treatment with BL-8040 and 8 hr following day 3 injection and the initial density of PB blast cells of the patients prior to the treatment (grey bars). The PB blast cell densities increased by 7.0 and 4.2 fold in responsive patients (CR and CRi, respectively), but no significant increase was observed in non-responsive patients (SD and PD).

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention, in some embodiments thereof, relates to uses of CXCR4 antagonists in the treatment of acute myeloid leukemia (AML). Specifically, the present invention can be used to identify AML patients for being responsive to the CXCR4 antagonists.

The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.

Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.

While reducing the present invention to practice, the present inventors have surprisingly uncovered that AML patients exhibiting low baseline density of blast cells in the peripheral blood even in the presence of high levels of blast cells in the bone marrow and/or strong mobilization of blast cell cells from the bone marrow to the peripheral blood, following administration of a CXCR4 antagonist as a single therapy, achieved high rates of remission as manifested even by complete remission (see details in Example 1 hereinbelow) by the combined treatment with CXCR4 antagonist and a chemotherapeutic agent.

Thus, the present teachings contemplate blast cell density in the peripheral blood or rates of mobilization of stromal cells to the peripheral blood as important clinical tools for establishing treatment of AML patients.

Thus, according to an aspect of the invention there is provided a method of selecting a treatment regimen for a subject having acute myeloid leukemia (AML), the method comprising measuring density of blast cells in peripheral blood and optionally bone marrow of the subject, the subject having been treated with a CXCR4 antagonist, wherein when the blast cell density in the peripheral blood is:

(i) less than 10% of the total peripheral white blood cells;

(ii) at least five-fold lower than the blast cell density in the bone marrow; and/or

(iii) at least two-fold higher one day or more following treatment with the CXCR4 antagonist,

the subject is selected for a combined treatment with the CXCR4 and a chemotherapeutic agent.

According to an additional or an alternative aspect of the invention there is provided a method of maximizing response to treatment of acute myeloid leukemia (AML), the method comprising:

(a) measuring a density of blast cells in peripheral blood and bone marrow of a subject with AML;

(b) administering to the subject a CXCR4 antagonist; and

(c) administering to the subject a therapeutically effective amount of the CXCR4 antagonist and a therapeutically effective amount of a chemotherapeutic agent if the blast cell density in the peripheral blood is:

(i) less than 10% of the total peripheral white blood cells;

(ii) at least five-fold lower than the blast cell density in the bone marrow; and/or

(iii) at least two-fold higher one day or more following step (b);

thereby maximizing response of the subject to AML treatment.

According to an additional or an alternative aspect of the invention there is provided a method of treating AML, the method comprising:

(a) identifying a subject with AML having a density of blast cells being less than 10% of the total white blood cells in the peripheral blood; and

(b) administering to the subject a therapeutically effective amount of a CXCR4-antagonist and a therapeutically effective amount of a chemotherapeutic agent, thereby treating the AML.

According to an additional or an alternative aspect of the invention there is provided a method of treating AML, the method comprising:

(a) identifying a subject with AML having a density of blast cells in the peripheral blood being at least five-fold lower than the density of blast cells in the bone marrow; and

(b) administering to the subject a therapeutically effective amount of a CXCR4-antagonist and a therapeutically effective amount of a chemotherapeutic agent, thereby treating the AML.

According to an additional or an alternative aspect of the invention there is provided a method of treating AML, the method comprising:

(a) identifying a subject with AML exhibiting at least two-fold increase in the density of blast cells in the peripheral blood at least one day following administration of a CXCR4 antagonist to the subject; and

(b) administering to the subject identified in step (a) a therapeutically effective amount of the CXCR4-antagonist and a therapeutically effective amount of a chemotherapeutic agent, thereby treating the AML.

According to an additional or an alternative aspect of the invention there is provided a CXCR4-antagonist and a chemotherapeutic agent in the treatment of AML in a subject in need thereof, wherein the subject is selected having been treated with the CXCR4-antagonist and exhibiting blast cell density in peripheral blood which is:

(i) less than 10% of the total peripheral white blood cells;

(ii) at least five-fold lower than the blast cell density in the bone marrow; and/or

(iii) at least two-fold higher one day or more following treatment with the CXCR4 antagonist,

The terms “treatment” or “treating” as used herein interchangeably refer to inhibiting, preventing or arresting the development of a pathology (disease, disorder or condition i.e., acute myeloid leukemia) and/or causing the reduction, remission, or regression of a pathology. Those of skill in the art will understand that various methodologies and assays can be used to assess the development of a pathology, and similarly, various methodologies and assays may be used to assess the reduction, remission or regression of a pathology.

As used herein, the term “preventing” refers to keeping a disease, disorder or condition from occurring in a subject who may be at risk for the disease, but has not yet been diagnosed as having the disease.

As used herein, the term “subject” includes mammals, preferably human beings at any age diagnosed with acute myeloid leukemia.

As mentioned the subject is diagnosed with acute myeloid leukemia.

The disease can be classified according to the FAB or WHO classification systems. Such classifications are provided infra where each of which represents a separate embodiment.

TABLE 1 WHO classification Name Description Includes: Acute myeloid AML with translocations between chromosome 8 and 21- leukemia with [t(8;21)(q22;q22);] RUNX1/RUNX1T1; (ICD-O 9896/3); recurrent genetic AML with inversions in chromosome 16-[inv(16)(p13.1q22)] abnormalities or internal translocations in it-[t(16;16)(p13.1;q22);] CBFB/MYH11; (ICD-O 9871/3); Acute promyelocytic leukemia with translocations between chromosome 15 and 17-[t(15;17)(q22;q12);] RARA/PML; (ICD-O 9866/3); AML with translocations between chromosome 9 and 11- [t(9;11)(p22;q23);] MLLT3/MLL; AML with translocations between chromosome 6 and 9- [t(6;9)(p23;q34);] DEK/NUP214; AML with inversions in chromosome 3-[inv(3)(q21q26.2)] or internal translocations in it-[t(3;3)(q21;q26.2);] RPN1/EVI1; Megakaryoblastic AML with translocations between chromosome 1 and 22-[t(1;22)(p13;q13);] RBM15/MKL1; AML with mutated NPM1 AML with mutated CEBPA AML with This category includes people who have had a prior documented myelodysplasia- myelodysplastic syndrome (MDS) or myeloproliferative disease related changes (MPD) that then has transformed into AML, or who have cytogenetic abnormalities characteristic for this type of AML (with previous history of MDS or MPD that has gone unnoticed in the past, but the cytogenetics is still suggestive of MDS/MPD history). This category of AML occurs most often in elderly people and often has a worse prognosis. Includes: AML with complex karyotype Unbalanced abnormalities AML with deletions of chromosome 7-[del(7q);] AML with deletions of chromosome 5-[del(5q);] AML with unbalanced chromosomal aberrations in chromosome 17-[i(17q)/t(17p);] AML with deletions of chromosome 13- [del(13q);] AML with deletions of chromosome 11- [del(11q);] AML with unbalanced chromosomal aberrations in chromosome 12-[del(12p)/t(12p);] AML with deletions of chromosome 9-[del(9q);] AML with aberrations in chromosome X- [idic(X)(q13);] Balanced abnormalities AML with translocations between chromosome 11 and 16-[t(11;16)(q23;q13.3);] unrelated to previous chemotherapy or ionizing radiation AML with translocations between chromosome 3 and 21-[t(3;21)(q26.2;q22.1);] unrelated to previous chemotherapy or ionizing radiation AML with translocations between chromosome 1 and 3-[t(1;3)(p36.3;q21.1);] AML with translocations between chromosome 2 and 11-[t(2;11)(p21;q23);] unrelated to previous chemotherapy or ionizing radiation AML with translocations between chromosome 5 and 12-[t(5;12)(q33;p12);] AML with translocations between chromosome 5 and 7-[t(5;7)(q33;q11.2);] AML with translocations between chromosome 5 and 17-[t(5;17)(q33;p13);] AML with translocations between chromosome 5 and 10-[t(5;10)(q33;q21);] AML with translocations between chromosome 3 and 5-[t(3;5)(q25;q34);] Therapy-related This category includes people who have had prior chemotherapy myeloid neoplasms and/or radiation and subsequently develop AML or MDS. These leukemias may be characterized by specific chromosomal abnormalities, and often carry a worse prognosis. Myeloid sarcoma This category includes myeloid sarcoma. Myeloid This category includes so-called “transient abnormal proliferations myelopoiesis” and “Myeloid leukemia associated with Down related to Down syndrome” syndrome Blastic This category includes so-called “blastic plasmacytoid dendritic plasmacytoid cell neoplasm” dendritic cell neoplasm AML not otherwise Includes subtypes of AML that do not fall into the above categorized categories AML with minimal differentiation AML without maturation AML with maturation Acute myelomonocytic leukemia Acute monoblastic and monocytic leukemia Acute erythroid leukemia Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelosis with myelofibrosis

TABLE 2 FAB subtypes Type Name Cytogenetics M0 acute blast cellic leukemia, minimally differentiated M1 acute blast cellic leukemia, without maturation M2 acute blast cellic leukemia, with granulocytic maturation t(8;21)(q22;q22), t(6;9) M3 promyelocytic, or acute promyelocytic leukemia (APL) t(15;17) M4 acute myelomonocytic leukemia inv(16)(p13q22), del(16q) M4eo myelomonocytic together with bone marrow eosinophilia inv(16), t(16;16) M5 acute monoblastic leukemia (M5a) or acute monocytic del (11q), t(9;11), leukemia (M5b) t(11;19) M6 acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) M7 acute megakaryoblastic leukemia t(1;22)

According to a specific embodiment the disease is characterized by a mutation in a FLT3 gene.

Internal tandem duplication in FLT3 gene is typically characterized by aberrant RNA transcripts which may stem from a simple internal duplication within exon 11; internal duplication (26 bp) with a 4-bp insertion; or a 136-bp sequence from the 3′ part of exon 11 to intron 11 and the first 16-bp sequence of exon 12 are duplicated with 1-bp insertion. Other abnormalities may also exist.

According to a specific embodiment, the FLT3 mutation results in activation of the protein.

In one embodiment the FLT3 mutation is a FLT3 internal-tandem duplication (ITD) mutation (Levis and Small, Leukemia 17: 1738-1752, 2003).

According to another embodiment the FLT3 mutation is a missense mutation at aspartic acid residue 835.

As used herein, the term “blast cells” refers to immature blood cells, such as blast cells, monoblasts and megakaryoblasts. According to a specific embodiment, the blast cells are myeloblasts. Methods of measuring the density of AML blast-cells in the bone marrow and in the peripheral blood are described, for example, in Cheson et al. [J Clin Oncol 21(24):4642-4649, 2003]; Lee et al. (Int. Jnl. Lab. Hem. 30: 349-364, 2008) and O'Connor, B. H. (A Color Atlas and Instructions Manual of Peripheral Cell Morphology, Lippincot Williams, 1984).

The phrase “CXCR4 antagonist” used herein refers to a composition capable of reducing CXCR-4 activation by at least 10%, as compared to same in the absence of the CXCR4 antagonist. According to a specific embodiment the CXCR4 antagonist is a competitive inhibitor. According to a specific embodiment the CXCR4 antagonist is a non-competitive inhibitor.

The CXCR4 antagonist of the present invention can be, but not limited to, a CXCR4-antagonistic peptide, a CXCR4-antagonistic polypeptide, a CXCR4-antagonistic antibody, or a CXCR4-antagonistic small molecule.

The CXCR4 antagonist of the present invention can be, but not limited to, AD-7049; AMD-3329; AMD-3465; AMD-8664; AMD-8897; AMD-3451; AMD-9370; AMD-3451; AMD-9370; GSK-812397; GMI-1215; GMI-1257; GMI-1359; CX-02; CX-05; CS-3955; KRH-1636; KRH-2731; KRH-3140; POL-2438; POL-3026; POL-6326; POL-6326; balixafortide; ONO-7161; F-50067; LY-2624587; ATI-2341; ATI-2342; ATI-2346; ATI-2347; ATI-2755; ATI-2756; ATI-2766; KRH-3166; LY-2510924; POL-5551; burixafor; TG-0054; ND-401; ND-4019; ALT-118; ALT-1188; MSX-122; WZ-40; CTCE-0013; CTCE-0021; CTCE-0214; ALX-0651; MPI-451936; GBV-4086; X4P-001; X4P-002; BKT-170; PF-06747143; MEDI-3185; BMS-936564; MDX-1338; ulocuplumab; CTCE-0012; VIR-5100; VIR-5103; AMD-070; AMD-11070; CTCE-9908; CTCE-9908/0019; PTX-9908; KRH-1120; T-134; NSC-645795; NSC-651016; NSC-655720; AMD-3100; GZ316455; JM-3100; Mozobil; SDZ-SID-791; SID-791; plerixafor; CD184-FK506 ADC; CD184-FK506; AT-009; NB-325; and/or CTCE-0324; and/or any combination thereof.

According to an embodiment of the invention, the CXCR4 antagonist of AMD-3100 (Plerixafor).

In some embodiments of the present invention the CXCR4 antagonist is a CXCR4-antagonistic peptide. As used herein, the term “peptide” encompasses native peptides (either degradation products, synthetically synthesized peptides or recombinant peptides) and peptidomimetics (typically, synthetically synthesized peptides), as well as peptoids and semipeptoids which are peptide analogs, which may have, for example, modifications rendering the peptides more stable while in a body or more capable of penetrating into cells.

According to a specific embodiment, the peptide is no more than 100 amino acids in length. According to a specific embodiment, the peptide is 5-100 amino acids in length. According to a specific embodiment, the peptide is 5-50 amino acids in length. According to a specific embodiment, the peptide is 5-20 amino acids in length. According to a specific embodiment, the peptide is 5-15 amino acids in length. According to a specific embodiment, the peptide is 10-20 amino acids in length. According to a specific embodiment, the peptide is 10-15 amino acids in length.

According to specific embodiments, the CXCR4-antagonistic peptides of the present invention are for example, 4F-benzoyl-TN14003 (SEQ ID NO: 1) analogs and derivatives and are structurally and functionally related to the peptides disclosed in patent applications WO 2002/020561 and WO 2004/020462, also known as “T-140 analogs”, as detailed hereinbelow.

In various particular embodiments, the T-140 analog or derivative has an amino acid sequence as set forth in the following formula (I) or a salt thereof:

(I) 1  2  3  4   5  6  7  8 9 10 11 12  13 14 A₁-A₂-A₃-Cys-Tyr-A₄-A₅-A₆-A₇-A₈-A₉-A₁₀-Cys-A₁₁

wherein:

A₁ is an arginine, lysine, ornithine, citrulline, alanine or glutamic acid residue or a N-α-substituted derivative of these amino acids, or A₁ is absent;

A₂ represents an arginine or glutamic acid residue if A₁ is present, or A₂ represents an arginine or glutamic acid residue or a N-α-substituted derivative of these amino acids if A₁ is absent;

A₃ represents an aromatic amino acid residue;

A₄, A₅ and A₉ each independently represents an arginine, lysine, ornithine, citrulline, alanine or glutamic acid residue;

A₆ represents a proline, glycine, ornithine, lysine, alanine, citrulline, arginine or glutamic acid residue;

A₇ represents a proline, glycine, ornithine, lysine, alanine, citrulline or arginine residue;

A₈ represents a tyrosine, phenylalanine, alanine, naphthylalanine, citrulline or glutamic acid residue;

A₁₀ represents a citrulline, glutamic acid, arginine or lysine residue;

A₁₁ represents an arginine, glutamic acid, lysine or citrulline residue wherein the C-terminal carboxyl may be derivatized;

and the cysteine residue of the 4-position or the 13-position can form a disulfide bond, and the amino acids can be of either L or D form.

Exemplary peptides according to formula (I) are peptides having an amino acid sequence as set forth in any one of SEQ ID NOS:1-72, as presented in Table 2 hereinbelow.

TABLE 2 T-140 and currently preferred T-140 analogs SEQ ID Analog NO: Amino acid sequence 4F-benzoyl-TN14003  1 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTC14003  2 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH AcTC14005  3 Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH AcTC14011  4 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH AcTC14013  5 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH AcTC14015  6 Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH AcTC14017  7 Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH AcTC14019  8 Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-OH AcTC14021  9 Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-OH AcTC14012 10 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTC14014 11 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ AcTC14016 12 Ac-Cit-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTC14018 13 Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTC14020 14 Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ AcTC14022 15 Ac-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Cit-Cit-Cys-Arg-NH₂ TE14001 16 H-DGlu-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TE14002 17 H-Arg-Glu-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TE14003 18 H-Arg-Arg-Nal-Cys-Tyr-Glu-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TE14004 19 H-Arg-Arg-Nal-Cys-Tyr-Arg-Glu-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TE14005 20 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-OH TE14006 21 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Glu-Cit-Cys-Arg-OH TE14007 22 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Glu-OH TE14011 23 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14012 24 H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14013 25 H-Arg-Arg-Nal-Cys-Tyr-DGlu-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14014 26 H-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14015 27 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ TE14016 28 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ AcTE14014 29 Ac-DGlu-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTE14015 30 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-DGlu-Arg-Cit-Cys-Arg-NH₂ AcTE14016 31 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-DGlu-Cys-Arg-NH₂ TF1: AcTE14011 32 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TF2: guanyl-TE14011 33 guanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TF3: TMguanyl- 34 TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14011 TF4: TMguanyl- 35 TMguanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14011 (2-14) TF5: 4F-benzoyl- 36 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14011 TF6: 2F-benzoyl- 37 2F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14011 TF7: APA-TE14011 38 APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (2-14) TF8: desamino-R- 39 desamino-R-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14011 (2-14) TF9: guanyl-TE14011 40 Guanyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ (2-14) TF10: succinyl- 41 succinyl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14011 (2-14) TF11: glutaryl- 42 glutaryl-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TE14011 (2-14) TF12: deaminoTMG- 43 deaminoTMG-APA-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ APA-TE14011 (2-14) TF15: H-Arg- 44 R-CH2-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ CH2NH-RTE14011 (2-14) TF17: TE14011 (2- 45 H-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ 14) TF18: TMguanyl- 46 TMguanyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TC14012 TF19: ACA-TC14012 47 ACA-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TF20: ACA-T140 48 ACA-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TZ14011 49 H-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTZ14011 50 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Arg-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTN14003 51 Ac-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ AcTN14005 52 Ac-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ 4F-benzoyl-TN14011- 53 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHMe Me 4F-benzoyl-TN14011- 54 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHEt Et 4F-benzoyl-TN14011- 55 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg-NHiPr iPr 4F-benzoyl-TN14011- 56 4F-benzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DGlu-Pro-Tyr-Arg-Cit-Cys-Arg- tyramine tyramine TA14001 57 H-Ala-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TA14005 58 H-Arg-Arg-Nal-Cys-Tyr-Ala-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TA14006 59 H-Arg-Arg-Nal-Cys-Tyr-Arg-Ala-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TA14007 60 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DAla-Pro-Tyr-Arg-Cit-Cys-Arg-OH TA14008 61 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Ala-Tyr-Arg-Cit-Cys-Arg-OH TA14009 62 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Ala-Arg-Cit-Cys-Arg-OH TA14010 63 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Ala-Cit-Cys-Arg-OH TC14001 64 H-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TC14003 65 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TN14003 66 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ TC14004 67 H-Arg-Arg-Nal-Cys-Tyr-Arg-Cit-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TC14012 68 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂ T-140 69 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH TC14011 70 H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH TC14005 71 H-Arg-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-OH TC14018 72 H-Cit-Arg-Nal-Cys-Tyr-Arg-Lys-DCit-Pro-Tyr-Arg-Cit-Cys-Arg-NH₂

According to a specific embodiment, in each one of SEQ ID NOS:1-72, two cysteine residues are coupled in a disulfide bond.

In another embodiment, the analog or derivative has an amino acid sequence as set forth in SEQ ID NO:65 (H-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-DLys-Pro-Tyr-Arg-Cit-Cys-Arg-OH; TC14003).

In another embodiment, the peptide used in the compositions and methods of the invention consists essentially of an amino acid sequence as set forth in SEQ ID NO:1. In another embodiment, the peptide used in the compositions and methods of the invention comprises an amino acid sequence as set forth in SEQ ID NO:1. In another embodiment, the peptide is at least 60%, at least 70% or at least 80% homologous to SEQ ID NO:1. In another embodiment, the peptide is at least 90% homologous to SEQ ID NO:1. In another embodiment, the peptide is at least about 95% homologous to SEQ ID NO:1. Each possibility represents a separate embodiment of the present invention.

In various other embodiments, the peptide is selected from SEQ ID NOS:1-72, wherein each possibility represents a separate embodiment of the present invention.

In another embodiment, the peptide has an amino acid sequence as set forth in any one of SEQ ID NOS: 1-4, 10, 46, 47, 51-56, 65, 66, 68, 70 and 71. In another embodiment, the peptide has an amino acid sequence as set forth in any one of SEQ ID NOS: 4, 10, 46, 47, 68 and 70. In another embodiment, the peptide has an amino acid sequence as set forth in any one of SEQ ID NOS:1, 2, 51, 65 and 66. In another embodiment, the peptide has an amino acid sequence as set forth in any one of SEQ ID NOS:53-56.

In an embodiment, the peptide has an amino acid sequence as set forth in SEQ ID NO:1. In another embodiment, the peptide has an amino acid sequence as set forth in SEQ ID NO:2. In another embodiment, the peptide has an amino acid sequence as set forth in SEQ ID NO:51. In another embodiment, the peptide has an amino acid sequence as set forth in SEQ ID NO:66.

According to a preferred embodiment, the CXCR4 antagonist is as set forth in SEQ ID NO: 1, also termed BL-8040 and BKT140.

Other CXCR4 peptide inhibitors (antagonists) include but are not limited to CTCE-9908 (Huang et al. 2009 Journal of Surgical Research 155:231-236), Fc131 analogs and nanobodies as specified in the citations below (each of which is incorporated herein by reference in its entirety):

Tan N C, Yu P, Kwon Y-U, Kodadek T. High-throughput evaluation of relative cell permeability between peptoids and peptides. Bioorg Med Chem. 2008; 16:5853-61.

Kwon Y-U, Kodadek T. Quantitative evaluation of the relative cell permeability of peptoids and peptides. J Am Chem Soc. 2007; 129:1508.

Miller S, Simon R, Ng S, Zuckermann R, Kerr J, Moos W. Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers. Drug Dev Res. 1995; 35:20-32.

Yoshikawa Y, Kobayashi K, Oishi S, Fujii N, Furuya T. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions. Bioorg Med Chem Lett. 2012; 22:2146-50.

-   Jaähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow K     Y, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W. CXCR4     nanobodies (VHH-based single variable domains) potently inhibit     chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl     Acad Sci USA. 2010; 107:20565-70.

Without being bound by theory it is suggested that peptides of the present invention induce growth arrest and/or death of myeloid leukemia cells.

The subject is evaluated for the density of blast cells in the peripheral blood and optionally in the bone marrow.

According to a specific embodiment, the subject is first treated with a CXCR4 antagonist (e.g., SEQ ID NO: 1), e.g., as a single agent.

Measuring blast density (percentage of total while blood cells in the respective organ i.e., peripheral blood or bone marrow) is performed following treatment with the CXCR4 antagonist (without the additional chemotherapy) and optionally prior to treatment therewith.

The subject is classified for administration of chemotherapy and the CXCR4 antagonist (e.g., SEQ ID NO: 1) when the blast cell density in said peripheral blood is:

-   -   (i) less than 10% or less than 5% or less than 3% of the total         peripheral white blood cells;     -   (ii) at least five-fold lower, at least four-fold lower, at         least three-fold or at least two-fold lower than said blast cell         density in said bone marrow; and/or     -   (iii) at least two-fold higher, at least 3 fold higher, at least         4 fold higher or at least 5 fold higher one day or more (e.g.,         1-4, 2-4, 2-3 days) following treatment with said CXCR4         antagonist (without the chemotherapy).

According to a specific embodiment, the subject is classified for administration of chemotherapy and the CXCR4 antagonist (SEQ ID NO: 1) when the blast cell density in said peripheral blood is:

-   -   (i) less than 10% or less than 5% or less than 3% of the total         peripheral white blood cells; and

(ii) at least five-fold lower, at least four-fold lower, at least three-fold or at least two-fold lower than said blast cell density in said bone marrow.

According to a specific embodiment, the subject is classified for administration of chemotherapy and the CXCR4 antagonist (SEQ ID NO: 1) when the blast cell density in said peripheral blood is:

-   -   (i) less than 10% or less than 5% or less than 3% of the total         peripheral white blood cells; and     -   (ii) at least two-fold higher, at least 3 fold higher, at least         4 fold higher or at least 5 fold higher one day or more (e.g.,         1-4, 2-4, 2-3 days) following treatment with said CXCR4         antagonist (without the chemotherapy).

According to a specific embodiment, the subject is classified for administration of chemotherapy and the CXCR4 antagonist (SEQ ID NO: 1) when the blast cell density in said peripheral blood is:

(i) at least five-fold lower, at least four-fold lower, at least three-fold or at least two-fold lower than said blast cell density in said bone marrow;

and

-   -   (ii) at least two-fold higher, at least 3 fold higher, at least         4 fold higher or at least 5 fold higher one day or more (e.g.,         1-4, 2-4, 2-3 days) following treatment with said CXCR4         antagonist (without the chemotherapy).

The CXCR4 antagonist in the combined treatment can be the same as that administered when provided alone or different. In one embodiment, the CXCR4 as a single agent and in the combined treatment is the same (e.g., SEQ ID NO: 1).

As used herein, the phrase “chemotherapeutic agent” refers to any chemical agent with therapeutic usefulness in the treatment of cancer. Chemotherapeutic agents as used herein encompass both chemical and biological agents. These agents function to inhibit a cellular activity upon which the cancer cell depends for continued survival. Categories of chemotherapeutic agents include alkylating/alkaloid agents, antimetabolites, hormones or hormone analogs, and miscellaneous antineoplastic drugs. Most if not all of these drugs are directly toxic to cancer cells and do not require immune stimulation. Suitable chemotherapeutic agents are described, for example, in Slapak and Kufe, Principles of Cancer Therapy, Chapter 86 in Harrison's Principles of Internal medicine, 14^(th) edition; Perry et al., Chemotherapeutic, Ch 17 in Abeloff, Clinical Oncology 2^(nd) ed., 2000 ChrchillLivingstone, Inc.; Baltzer L. and Berkery R. (eds): Oncology Pocket Guide to Chemotherapeutic, 2^(nd) ed. St. Luois, mosby-Year Book, 1995; Fischer D. S., Knobf M. F., Durivage H. J. (eds): The Cancer Chemotherapeutic Handbook, 4^(th) ed. St. Luois, Mosby-Year Handbook.

The chemotherapeutic agent of the present invention can be, but not limited to, cytarabine (cytosine arabinoside, Ara-C, Cytosar-U), asprin, sulindac, curcumin, alkylating agents including: nitrogen mustards, such as mechlor-ethamine, cyclophosphamide, ifosfamide, melphalan and chlorambucil; nitrosoureas, such as carmustine (BCNU), lomustine (CCNU), and semustine (methyl-CCNU); thylenimines/methylmelamine such as thriethylenemelamine (TEM), triethylene, thiophosphoramide (thiotepa), hexamethylmelamine (HMM, altretamine); alkyl sulfonates such as busulfan; triazines such as dacarbazine (DTIC); antimetabolites including folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5-fluorouracil, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2.difluorodeoxycytidine, purine analogs such as 6-mercaptopurine, 6-thioguanine, azathioprine, 2′-deoxycoformycin (pentostatin), erythrohydroxynonyladenine (EHNA), fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA); natural products including antimitotic drugs such as paclitaxel, vinca alkaloids including vinblastine (VLB), vincristine, and vinorelbine, taxotere, estramustine, and estramustine phosphate; epipodophylotoxins such as etoposide and teniposide; antibiotics, such as actimomycin D, daunomycin (rubidomycin), doxorubicin, mitoxantrone, idarubicin, bleomycins, plicamycin (mithramycin), mitomycinC, and actinomycin; enzymes such as L-asparaginase, cytokines such as interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, TNF-beta and GM-CSF, anti-angiogenic factors, such as angiostatin and endostatin, inhibitors of FGF or VEGF such as soluble forms of receptors for angiogenic factors, including soluble VGF/VEGF receptors, platinum coordination complexes such as cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea, methylhydrazine derivatives including Nmethylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane (o,p′-DDD) and aminoglutethimide; hormones and antagonists including adrenocorticosteroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide; progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate; estrogen such as diethylstilbestrol and ethinyl estradiol equivalents; antiestrogen such as tamoxifen; androgens including testosterone propionate and fluoxymesterone/equivalents; antiandrogens such as flutamide, gonadotropin-releasing hormone analogs and leuprolide; non-steroidal antiandrogens such as flutamide; kinase inhibitors, histone deacetylase inhibitors, methylation inhibitors, proteasome inhibitors, monoclonal antibodies, oxidants, anti-oxidants, telomerase inhibitors, BH3 mimetics, ubiquitin ligase inhibitors, stat inhibitors and receptor tyrosin kinase inhibitors such as imatinib mesylate (marketed as Gleevac or Glivac) and erlotinib (an EGF receptor inhibitor) now marketed as Tarveca; and anti-virals such as oseltamivir phosphate, Amphotericin B, and palivizumab.

In some embodiments the chemotherapeutic agent of the present invention is cytarabine (cytosine arabinoside, Ara-C, Cytosar-U), quizartinib (AC220), sorafenib (BAY 43-9006), lestaurtinib (CEP-701), midostaurin (PKC412), carboplatin, carmustine, chlorambucil, dacarbazine, ifosfamide, lomustine, mechlorethamine, procarbazine, pentostatin, (2′deoxycoformycin), etoposide, teniposide, topotecan, vinblastine, vincristine, paclitaxel, dexamethasone, methylprednisolone, prednisone, all-trans retinoic acid, arsenic trioxide, interferon-alpha, rituximab (Rituxan®), gemtuzumab ozogamicin, imatinib mesylate, Cytosar-U), melphalan, busulfan (Myleran®), thiotepa, bleomycin, platinum (cisplatin), cyclophosphamide, Cytoxan®), daunorubicin, doxorubicin, idarubicin, mitoxantrone, 5-azacytidine, cladribine, fludarabine, hydroxyurea, 6-mercaptopurine, methotrexate, 6-thioguanine, or any combination thereof.

In an embodiment the chemotherapeutic agent is cytarabine (ARA-C).

In an embodiment the chemotherapeutic agent is quizartinib (AC220).

Once the subject is qualified for a combined treatment, the CXCR4 antagonist and the chemotherapeutic agent of the invention can be administered concomitantly (at about the same time in a single formulation or in separate formulations) or sequentially.

In some embodiments the CXCR4 antagonist is administered at least 1 hour, at least 2 hours, at least 4 hours, at least 8 hours, at least 12 hours, at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, or at least 1 month prior to the administration of the chemotherapeutic agent.

In some embodiments the CXCR4 antagonist and the chemotherapy are administered sequentially by within 1 hour, within 2 hours, within 4 hours, within 8 hours, within 12 hours, within 1 day, within 2 days, within 3 days, within 4 days, within 5 days, within 6 days, within 1 week, or within 1 month.

According to some embodiments, the CXCR4-antagonist is administered between 1 to 24 hours prior to the administration of the chemotherapeutic agent. According to some embodiments, the CXCR4-antagonist is administered between 1 to 8 hours prior to the administration of the chemotherapeutic agent.

The CXCR4 antagonist and the chemotherapeutic agent of the invention can each be administered to the subject as active ingredients per se, or in a pharmaceutical composition(s) where each of the active ingredients is mixed with suitable carriers or excipients.

As used herein a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

Herein the term “active ingredient” refers to the peptides accountable for the biological effect. Optionally, a plurality of active ingredient may be included in the formulation such as chemotherapeutic, radiation agents and the like, as further described hereinbelow.

Hereinafter, the phrases “physiologically acceptable carrier” and “pharmaceutically acceptable carrier”, which may be used interchangeably, refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound.

Herein, the term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

Techniques for formulation and administration of drugs may be found in the latest edition of “Remington's Pharmaceutical Sciences”, Mack Publishing Co., Easton, Pa., which is herein fully incorporated by reference (Remington: The Science and Practice of Pharmacy, Gennaro, A., Lippincott, Williams & Wilkins, Philadelphia, Pa., 20^(th) ed, 2000).

Pharmaceutical compositions of the present invention may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations that can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

In one embodiment, the CXCR4 antagonist of the invention or the pharmaceutical composition comprising same is administered subcutaneously.

In another embodiment, the chemotherapeutic agent of the invention or the pharmaceutical composition comprising same is administered intravenously.

In another embodiment, the chemotherapeutic agent of the invention or the pharmaceutical composition comprising same is administered orally.

For injection, the active ingredients of the pharmaceutical composition may be formulated in aqueous solutions (e.g., WFI), preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological salt buffer.

Pharmaceutical compositions for potential administration include aqueous solutions of the active preparation in water-soluble form. Additionally, suspensions of the active ingredients may be prepared as appropriate oily or water-based injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters such as ethyl oleate, triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the active ingredients, to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., a sterile, pyrogen-free, water-based solution, before use.

Alternative embodiments include depots providing sustained release or prolonged duration of activity of the active ingredient in the subject, as are well known in the art.

Pharmaceutical compositions suitable for use in the context of the present invention include compositions wherein the active ingredients are contained in an amount effective to achieve the intended purpose. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

For any preparation used in the methods of the invention, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.

Toxicity and therapeutic efficacy of the active ingredients described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals (see the Examples section which follows, and Sekido et al. 2002 Cancer Genet Cytogenet 137(1):33-42). The data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in human. The dosage may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl, et al., 1975, in “The Pharmacological Basis of Therapeutics”, Ch. 1 p. 1).

In some embodiments the daily dose of the CXCR4 antagonist (e.g., SEQ ID NO: 1) of the invention or the pharmaceutical composition comprising same is ranging between 0.1 to 10 mg/kg of body weight, between 0.1 to 2 mg/kg of body weight, between 0.1 to 1 mg/kg of body weight, between 0.3 to 10 mg/kg of body weight, between 0.3 to 2 mg/kg of body weight, between 0.3 to 1 mg/kg of body weight or between 0.3 to 0.9 mg/kg of body weight.

In some embodiments the daily dose the chemotherapeutic agent of the invention (e.g., cytarabine) or the pharmaceutical composition comprising same is ranging between 1 to 10 g per square meter of body area, between 1.5 to 5 g per square meter of body area or between 2 to 4 g per square meter of body area.

With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment or make other alteration to treatment regimen. The dosing schedule can vary depending on a number of clinical factors, such as blood counts (e.g., red or white blood cell levels, hemoglobin level, etc.) the subject sensitivity to the peptide and/or the chemotherapeutic agent. The desired dose can be administered at one time or divided into sub-doses, e.g., 2-4 sub-doses and administered over a period of time, e.g., at appropriate intervals through the day or other appropriate schedule. Such sub-doses can be administered as unit dosage forms.

In some embodiments the CXCR4 antagonist of the invention is administered for a period of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days, at least 1 week, at least 2 weeks, at least 3 weeks, at least 1 month, or at least 2 months prior to administering of the chemotherapeutic agent.

The active ingredients described herein can be packaged in an article of manufacture which comprises at least two separate containers. One container packaging the CXCR-4 peptide antagonist (e.g., peptide set forth in SEQ ID NO: 1) and another container which packages the chemotherapy (e.g., Ara-C). The article of manufacture may comprise a label and/or instructions for the treatment of myeloid leukemia (e.g., AML).

Alternatively or additionally, the CXCR4 antagonist and the chemotherapeutic agent can be formulated in a pharmaceutical composition as described above as a co-formulation.

Thus, compositions (CXCR4 antagonist, chemotherapeutic agent, or a combination of same) and/or articles of some embodiments of the invention may, if desired, be presented in a pack or dispenser device, such as an FDA approved kit, which may contain one or more unit dosage forms containing the active ingredient. The pack may, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. The pack or dispenser may also be accommodated by a notice associated with the container in a form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the compositions or human or veterinary administration. Such notice, for example, may be of labeling approved by the U.S. Food and Drug Administration for prescription drugs or of an approved product insert. Compositions comprising a preparation of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container (e.g., lyophilized vial), and labeled for treatment of an indicated condition, as is further detailed above.

As used herein the term “about” refers to ±10%.

As used herein the term “method” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.

It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.

Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.

EXAMPLES

Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non-limiting fashion.

Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, “Molecular Cloning: A laboratory Manual” Sambrook et al., (1989); “Current Protocols in Molecular Biology” Volumes I-III Ausubel, R. M., Ed. (1994); Ausubel et al., “Current Protocols in Molecular Biology”, John Wiley and Sons, Baltimore, Md. (1989); Perbal, “A Practical Guide to Molecular Cloning”, John Wiley & Sons, New York (1988); Watson et al., “Recombinant DNA”, Scientific American Books, New York; Birren et al. (Eds.) “Genome Analysis: A Laboratory Manual Series”, Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998); methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531; 5,192,659 and 5,272,057; “Cell Biology: A Laboratory Handbook”, Volumes I-III Cellis, J. E., Ed. (1994); “Culture of Animal Cells—A Manual of Basic Technique” by Freshney, Wiley-Liss, N.Y. (1994), Third Edition; “Current Protocols in Immunology” Volumes I-Ill Coligan J. E., Ed. (1994); Stites et al. (Eds.), “Basic and Clinical Immunology” (8th Edition), Appleton & Lange, Norwalk, Conn. (1994); Mishell and Shiigi (Eds.), “Selected Methods in Cellular Immunology”, W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219; 5,011,771 and 5,281,521; “Oligonucleotide Synthesis” Gait, M. J., Ed. (1984); “Nucleic Acid Hybridization” Hames, B. D., and Higgins S. J., Eds. (1985); “Transcription and Translation” Hames, B. D., and Higgins S. J., Eds. (1984); “Animal Cell Culture” Freshney, R. I., Ed. (1986); “Immobilized Cells and Enzymes” IRL Press, (1986); “A Practical Guide to Molecular Cloning” Perbal, B., (1984) and “Methods in Enzymology” Vol. 1-317, Academic Press; “PCR Protocols: A Guide To Methods And Applications”, Academic Press, San Diego, Calif. (1990); Marshak et al., “Strategies for Protein Purification and Characterization—A Laboratory Course Manual” CSHL Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference.

Example I Correlation Between Blast Cells Mobilization in AML Patients Following BL-8040 Administration and the Clinical Response Materials and Methods

Drugs

Lyophilized 4F-benzoyl-TN14003 (BL-8040) was manufactured in accordance with cGMP by MSD/N.V. (Organon, Kloosterstraat 6, 5349 AB, Os s, Netherlands).

Cytarabine (Cytosine arabinoside; ARA-C) was purchased from Hadassah cytotoxica pharmacy (Israel).

Clinical Trial Design

In an open-label, single arm, phase 1/2 study, patients diagnosed with AML with relapsed or refractory disease received a once daily subcutaneous (SC) dose of BL-8040 as monotherapy on days 1-2 followed by the same dose of BL-8040 plus Ara-C (1.5 g/m2 for patients ≥60; 3 g/m2 for patients <60) on days 3-7. Six dose levels of BL-8040 (0.5-2.0 mg/kg) were tested in the dose escalation phase with 1.5 mg/kg selected for the expansion phase. Extensive pharmacodynamics (PD) parameters such as the extent of mobilization were assessed during the study. Clinical response to treatment was determined by BM biopsy on day 30.

Measuring Blast-Cell Density in Peripheral Blood (PB) and Bone Marrow (BM)

Bone marrow blast-cell counts were performed using procedures essentially as described by Lee et al. (Int. Jnl. Lab. Hem. 30: 349-364, 2008).

Peripheral blast-cell counts were performed using procedures essentially as described by O'Connor, B. H., A Color Atlas and Instructions Manual of Peripheral Cell Morphology, Lippincot Williams, 1984.

Clinical Response

Clinical responses to ANL treatment were determined according to the standards of the international working group for AML (Cheson et al., J. Clin. Oncol. 21: 4642-4649, 2003; Döhner et al., Blood 115: 453-474, 2010; and de Greef et al., British Journal of Hematology 128: 184-91, 2005), which are summarized in Table 1 below.

TABLE 1 Clinical Responses to AML Treatment Category Definition Complete remission (CR) Bone marrow blasts <5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count >1.0 × 10⁹/L (1000/μL); platelet count >100 × 10⁹/L (100,000/μL); independence of red cell transfusions. CR with incomplete recovery All CR criteria except for: (CRi, CRp) residual neutropenia (<1.0 × 10⁹/L [1000/μL]) or thrombocytopenia also termed CRp (<100 × 10⁹/L [100,000/μL]) Partial remission (PR) Relevant in the setting of phase 1 and 2 clinical trials only; all hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50% Stable disease (SD) Stable disease was defined by the absence of a complete or partial response, or antileukemic effect, and no progressive disease. Progressive disease (PD) Progressive disease was defined as a greater than 25% relative increase in blasts in the peripheral blood or bone marrow compared to before start of treatment.

Results

Treated patients that achieved complete remission (CR) or complete remission with incomplete recovery (CRi or CRp) were considered responsive. Among all the patients receiving at least 1 mg/kg of BL-8040 there was essentially no difference between the responsive and non-responsive patients in their baseline BM blast-cell density (37.8% and 40.8%, respectively; FIG. 1). Measurement was done prior to the combined treatment of SEQ ID NO:1 with cytarabine.

On the other hand, surprisingly, the baseline PB blast-cell density was substantially lower in responsive patients, as compared with non-responsive patients (2.9% and 19.3%, respectively; FIG. 2). Measurement was done prior to the combined treatment of SEQ ID NO:1 with cytarabine. The PB blast-cell density of non-responsive patients did not increase (i.e., remained at the same or lower level than baseline) after 2 or 3 days following first administration of BL-8040. On the other hand, surprisingly, PB blast-cell density of responsive patients increased by 3.7 and 3.8 fold after 2 or 3 days following first administration of BL-8040, respectively (FIGS. 3-5). More specifically, FIG. 5 shows data of day 3 8 hour post injection which is after the initiation of the cytarabine administration (initiated 4 hours post SEQ ID NO: 1 that day). FIGS. 3 and 4 are prior to the combined treatment with cytarabine.

These results indicate that AML patients having low baseline BM blast-cell density and/or capable of having substantial increase of PB blast-cell density following BL-8040 administration, are likely to achieve complete remission successfully when treated with BL-8040 combined with chemotherapy.

All publications, patents and patent applications mentioned in this specification are herein incorporated in their entirety by into the specification, to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. 

What is claimed is:
 1. A method of treating Acute Myeloid Leukemia (AML) in a human subject, the method comprising: a) administering a CXCR4 antagonist without a chemotherapeutic agent in said human subject, b) analyzing blast cells in the peripheral blood of said human subject at least one day following method step a), and c) co-administering a CXCR4 antagonist with a chemotherapeutic agent in said human subject if there is at least a two-fold increase in blast cells in the peripheral blood of said subject thereby treating AML in said subject.
 2. The method of claim 1, wherein said CXCR4-antagonist is as set forth in SEQ ID NO:
 1. 3. The method of claim 2, wherein said chemotherapeutic agent comprises cytarabine (ARA-C).
 4. The method of claim 1, wherein said subject exhibits at least a two-fold increase in blast cells in the peripheral blood 2 to 4 days following administration of said CXCR4 antagonist without said chemotherapeutic agent. 